Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03248882 · ClinicalTrials.gov registry record · Phase 2

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

A Phase 2 study, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
305
Enrollment target

NCT03248882: Completed Phase 2 study, sponsored by Pfizer.

NCT03248882 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 305 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (129% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03248882, a Phase 2 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
305 participants
Enrollment target

Study Summary

Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Primary Outcome

MRI-PDFF utilized a gradient echo sequence with low flip angle (FA) to minimize T1 bias, corrected T2\* decay (due to iron overload) via modeling of the fat signal as a superposition of multiple frequency components from 5 different lipid types, and was applied in each of the 9 Couinaud segments. This technique improved fat quantification accuracy for the entire liver permitting quantification of small differences/changes following pharmacological intervention.

Interventions

  • DRUG Placebo
  • DRUG PF-05221304

Trial Details

FieldValue
Enrollment Target 305 participants
Start Date 2017-08-22
Est. Completion 2019-03-27
Phase Phase 2
Pfizer

1,845 total trials

What the finished NCT03248882 record still lists

NCT03248882 is an interventional study that assigns participants to a tested intervention. The registered 305 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (129% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03248882 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03248882 about?

NCT03248882 is a clinical study titled "Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)". Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

What is the current status of trial NCT03248882?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 305 participants. The study started on 2017-08-22. Estimated completion is 2019-03-27.

What interventions are being tested in trial NCT03248882?

The interventions under investigation include: Placebo (DRUG), PF-05221304 (DRUG).

Who is sponsoring clinical trial NCT03248882?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03248882's enrollment target sits among peer trials

305 166th of 2000 higher than 1,835 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04107181 · 305 participants · NA

    Pilot Study for Speculum Free Cervical Cancer Screening

  • NCT05399056 · 305 participants · NA

    Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling

  • NCT05078970 · 306 participants · NA

    Advancing Suicide Intervention Strategies for Teens During High Risk Periods

  • NCT05843695 · 306 participants · NA

    Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03248882, the US trial registry maintained by the National Library of Medicine. NCT03248882 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.